Dietary Supplement Use in Cancer Care: Help or Harm

Hematology/Oncology Clinics of North America

Volumn 22, Issue 4, 2008, Pages 581-617

  Hardy, Mary L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DOCETAXEL; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; IMATINIB; IRINOTECAN; SABAL EXTRACT; SILIBININ; SILYMARIN; VITAMIN;

ALTERNATIVE MEDICINE; ANXIETY; AREA UNDER THE CURVE; BREAST CANCER; CANCER RISK; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; DEPRESSION; DIET SUPPLEMENTATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; GENETIC ANALYSIS; HEAD AND NECK CANCER; HUMAN; INTERPERSONAL COMMUNICATION; LIVER TOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

ANTIOXIDANTS; CACHEXIA; COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; GASTROINTESTINAL DISEASES; HERB-DRUG INTERACTIONS; HOT FLASHES; HUMANS; LYMPHEDEMA; NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYTOTHERAPY; PLANT PREPARATIONS; RADIATION INJURIES; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; STOMATITIS;

EID: 47049088074     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2008.04.012     Document Type: Review

References (201)

1. D'Andrea G.M. Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin 55 5 (2005) 319-321
2. Yates J.S., Mustian K.M., Morrow G.R., et al. Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer 13 10 (2005) 806-811
3. Molassiotis A., Ozden G., Platin N., et al. Complementary and alternative medicine use in patients with head and neck cancers in Europe. Eur J Cancer Care (Engl) 15 1 (2006) 19-24
4. Vapiwala N., Mick R., Hampshire M.K., Metz J.M., and DeNittis A.S. Patient initiation of complementary and alternative medical therapies (CAM) following cancer diagnosis. Cancer J 12 6 (2006) 467-474
5. DiGianni L.M., Kim H.T., Emmons K., Gelman R., Kalkbrenner K.J., and Garber J.E. Complementary medicine use among women enrolled in a genetic testing program. Cancer Epidemiol Biomarkers Prev 12 4 (2003) 321-326
6. Digianni L.M., Rue M., Emmons K., and Garber J.E. Complementary medicine use before and 1 year following genetic testing for BRCA1/2 mutations. Cancer Epidemiol Biomarkers Prev 15 1 (2006) 70-75
7. Gupta D., Lis C.G., Birdsall T.C., and Grutsch J.F. The use of dietary supplements in a community hospital comprehensive cancer center: implications for conventional cancer care. Support Care Cancer 13 11 (2005) 912-919
8. Sparber A., Bauer L., Curt G., et al. Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum 27 4 (2000) 623-630
9. Hlubocky F.J., Ratain M.J., Wen M., and Daugherty C.K. Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making. J Clin Oncol 25 5 (2007) 548-554
10. Swarup A.B., Barrett W., and Jazieh A.R. The use of complementary and alternative medicine by cancer patients undergoing radiation therapy. Am J Clin Oncol 29 5 (2006) 468-473
11. Hann D., Baker F., Denniston M., and Entrekin N. Long-term breast cancer survivors' use of complementary therapies: perceived impact on recovery and prevention of recurrence. Integr Cancer Ther 4 1 (2005) 14-20
12. Jazieh A.R., Kopp M., Foraida M., et al. The use of dietary supplements by veterans with cancer. J Altern Complement Med 10 3 (2004) 560-564
13. Tasaki K., Maskarinec G., Shumay D.M., Tatsumura Y., and Kakai H. Communication between physicians and cancer patients about complementary and alternative medicine: exploring patients' perspectives. Psychooncology 11 3 (2002) 212-220
14. Verhoef M.J., White M.A., and Doll R. Cancer patients' expectations of the role of family physicians in communication about complementary therapies. Cancer Prev Control 3 3 (1999) 181-187
15. Hyodo I., Eguchi K., Nishina T., et al. Perceptions and attitudes of clinical oncologists on complementary and alternative medicine: a nationwide survey in Japan. Cancer 97 11 (2003) 2861-2868
16. Bourgeault I.L. Physicians' attitudes toward patients' use of alternative cancer therapies. Cmaj 155 12 (1996) 1679-1685
17. Richardson M.A., Masse L.C., Nanny K., and Sanders C. Discrepant views of oncologists and cancer patients on complementary/alternative medicine. Support Care Cancer 12 11 (2004) 797-804
18. Henderson J.W., and Donatelle R.J. Complementary and alternative medicine use by women after completion of allopathic treatment for breast cancer. Altern Ther Health Med 10 1 (2004) 52-57
19. Hann D.M., Baker F., Roberts C.S., et al. Use of complementary therapies among breast and prostate cancer patients during treatment: a multisite study. Integr Cancer Ther 4 4 (2005) 294-300
20. Verhoef M.J., Mulkins A., Carlson L.E., Hilsden R.J., and Kania A. Assessing the role of evidence in patients' evaluation of complementary therapies: a quality study. Integr Cancer Ther 6 4 (2007) 345-353
21. Bauer B., Lee M., Wahner-Roedler D., Brown S., Pankratz S., and Elkin P.L. A controlled trial of physicians' amd patients' abilities to distinguish authoritative from misleading complementary and alternative medicine Web sites. Journal of Cancer Integrative Medicine 1 1 (2003) 48-54
22. Ernst E., and Cassileth B.R. How useful are unconventional cancer treatments?. Eur J Cancer 35 11 (1999) 1608-1613
23. Chang E.Y., Glissmeyer M., Tonnes S., Hudson T., and Johnson N. Outcomes of breast cancer in patients who use alternative therapies as primary treatment. Am J Surg 192 4 (2006) 471-473
24. Miller D.R., Anderson G.T., Stark J.J., Granick J.L., and Richardson D. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 16 11 (1998) 3649-3655
25. Loprinzi C.L., Levitt R., Barton D.L., et al. Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer 104 1 (2005) 176-182
26. Moertel C.G., Fleming T.R., Rubin J., et al. A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med 306 4 (1982) 201-206
27. Helyer L.K., Chin S., Chui B.K., et al. The use of complementary and alternative medicines among patients with locally advanced breast cancer-a descriptive study. BMC Cancer 6 (2006) 39
28. Cassileth B.R., Lusk E.J., Strouse T.B., and Bodenheimer B.J. Contemporary unorthodox treatments in cancer medicine. A study of patients, treatments, and practitioners. Ann Intern Med 101 1 (1984) 105-112
29. Cassileth B.R., Lusk E.J., Guerry D., et al. Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. N Engl J Med 324 17 (1991) 1180-1185
30. Cosyns J.P. Aristolochic acid and "Chinese herbs nephropathy": a review of the evidence to date. Drug Saf 26 1 (2003) 33-48
31. White J. PC-SPES-a lesson for future dietary supplement research. J Natl Cancer Inst 94 17 (2002) 1261-1263
32. Guns E.S., Goldenberg S.L., and Brown P.N. Mass spectral analysis of PC-SPES confirms the presence of diethylstilbestrol. Can J Urol 9 6 (2002) 1684-1688 discussion 1689
33. Fact Sheet Dietary Supplement Current Good Manufacturing Practices (CGMPs) and Interim Final Rule (IFR) Facts. Available at: http://www.cfsan.fda.gov/∼dms/dscgmps6.html.
34. In: McGuffin M., Hobbs C., Upton R., and Goldberg A. (Eds). American Herbal Product Association's Botanical Safety Handbook (1997), CRC Press, Boca Raton, Florida 129-160
35. Seeff L.B. Herbal hepatotoxicity. Clin Liver Dis 11 3 (2007) 577-596 vii
36. Blumenthal M. European Health Agencies Recommend Liver Warnings on Black Cohosh Products. Herbalgram 72 (2006) 56-58
37. Report on Workshop on the Safety of Black Cohosh in Clinical Studies. Paper presented at: Workshop on the Safety of Black Cohosh in Clinical Studies, 2004; National Institutes of Health Bethesda, Maryland. Available at: http://nccam.nih.gov/news/pastmeetings/blackcohosh_mtngsumm.html.
38. Sparreboom A., Cox M.C., Acharya M.R., and Figg W.D. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22 12 (2004) 2489-2503
39. Yeung K.S., and Gubili J. Clinical guide to herb-drug interactions in oncology. J Soc Integr Oncol 5 3 (2007) 113-117
40. Meijerman I., Beijnen J.H., and Schellens J.H. Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist 11 7 (2006) 742-752
41. McCune J.S., Hatfield A.J., Blackburn A.A., Leith P.O., Livingston R.B., and Ellis G.K. Potential of chemotherapy-herb interactions in adult cancer patients. Support Care Cancer 12 6 (2004) 454-462
42. Block K.I., and Gyllenhaal C. Clinical corner: herb-drug interactions in cancer chemotherapy: theoretical concerns regarding drug metabolizing enzymes. Integr Cancer Ther 1 1 (2002) 83-89
43. Werneke U., Earl J., Seydel C., Horn O., Crichton P., and Fannon D. Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 90 2 (2004) 408-413
44. Skalli S., Zaid A., and Soulaymani R. Drug interactions with herbal medicines. Ther Drug Monit 29 6 (2007) 679-686
45. Cox M.C., Low J., Lee J., et al. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res 12 15 (2006) 4636-4640
46. van Erp N.P., Baker S.D., Zhao M., et al. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 11 21 (2005) 7800-7806
47. Smith P., Bullock J.M., Booker B.M., Haas C.E., Berenson C.S., and Jusko W.J. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 24 11 (2004) 1508-1514
48. Frye R.F., Fitzgerald S.M., Lagattuta T.F., Hruska M.W., and Egorin M.J. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 76 4 (2004) 323-329
49. Mathijssen R.H., Verweij J., de Bruijn P., Loos W.J., and Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 94 16 (2002) 1247-1249
50. Mannel M. Drug interactions with St John's wort: mechanisms and clinical implications. Drug Saf 27 11 (2004) 773-797
51. Kumar N.B., Allen K., and Bell H. Perioperative herbal supplement use in cancer patients: potential implications and recommendations for presurgical screening. Cancer Control 12 3 (2005) 149-157
52. Beckert B.W., Concannon M.J., Henry S.L., Smith D.S., and Puckett C.L. The effect of herbal medicines on platelet function: an in vivo experiment and review of the literature. Plast Reconstr Surg 120 7 (2007) 2044-2050
53. Wittkowsky A.K. Dietary supplements, herbs and oral anticoagulants: the nature of the evidence. J Thromb Thrombolysis 25 1 (2008) 72-77
54. Piersen C.E. Phytoestrogens in botanical dietary supplements: implications for cancer. Integr Cancer Ther 2 2 (2003) 120-138
55. Beck V., Unterrieder E., Krenn L., Kubelka W., and Jungbauer A. Comparison of hormonal activity (estrogen, androgen and progestin) of standardized plant extracts for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol 84 2-3 (2003) 259-268
56. Lupu R., Mehmi I., Atlas E., et al. Black cohosh, a menopausal remedy, does not have estrogenic activity and does not promote breast cancer cell growth. Int J Oncol 23 5 (2003) 1407-1412
57. Walji R., Boon H., Guns E., Oneschuk D., and Younus J. Black cohosh (Cimicifuga racemosa [L.] Nutt.): safety and efficacy for cancer patients. Support Care Cancer 15 8 (2007) 913-921
58. Raus K., Brucker C., Gorkow C., and Wuttke W. First-time proof of endometrial safety of the special black cohosh extract (Actaea or Cimicifuga racemosa extract) CR BNO 1055. Menopause 13 4 (2006) 678-691
59. Hirschberg A.L., Edlund M., Svane G., Azavedo E., Skoog L., and von Schoultz B. An isopropanolic extract of black cohosh does not increase mammographic breast density or breast cell proliferation in postmenopausal women. Menopause 14 1 (2007) 89-96
60. Burdette J.E., Liu J., Chen S.N., et al. Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. J Agric Food Chem 51 19 (2003) 5661-5670
61. Shekelle P., Hardy M.L., Coulter I., et al. Effect of the supplemental use of antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cancer. Evid Rep Technol Assess (Summ) 75 (2003) 1-3
62. Omenn G.S. Chemoprevention of lung cancers: lessons from CARET, the beta-carotene and retinol efficacy trial, and prospects for the future. Eur J Cancer Prev 16 3 (2007) 184-191
63. Prasad K.N., Cole W.C., Kumar B., and Prasad K.C. Scientific rationale for using high-dose multiple micronutrients as an adjunct to standard and experimental cancer therapies. J Am Coll Nutr 20 5 Suppl (2001) 450S-63S; discussion 473S-5S
64. Moss R.W. Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants?. Integr Cancer Ther 5 1 (2006) 63-82
65. Simone II C.B., Simone N.L., Simone V., and Simone C.B. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, Part 2. Altern Ther Health Med 13 2 (2007) 40-47
66. Simone II C.B., Simone N.L., Simone V., and Simone C.B. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1. Altern Ther Health Med 13 1 (2007) 22-28
67. Prasad K.N. Rationale for using multiple antioxidants in protecting humans against low doses of ionizing radiation. Br J Radiol 78 930 (2005) 485-492
68. Bairati I., Meyer F., Gelinas M., et al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol 23 24 (2005) 5805-5813
69. Bairati I., Meyer F., Jobin E., et al. Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients. Int J Cancer 119 9 (2006) 2221-2224
70. Lesperance M.L., Olivotto I.A., Forde N., et al. Mega-dose vitamins and minerals in the treatment of non-metastatic breast cancer: an historical cohort study. Breast Cancer Res Treat 76 2 (2002) 137-143
71. Pathak A.K., Bhutani M., Guleria R., et al. Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer. J Am Coll Nutr 24 1 (2005) 16-21
72. Cameron E., and Pauling L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 75 9 (1978) 4538-4542
73. Moertel C.G., Fleming T.R., Creagan E.T., Rubin J., O'Connell M.J., and Ames M.M. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 312 3 (1985) 137-141
74. Creagan E.T., Moertel C.G., O'Fallon J.R., et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301 13 (1979) 687-690
75. Drisko J.A., Chapman J., and Hunter V.J. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. J Am Coll Nutr 22 2 (2003) 118-123
76. Drisko J.A., Chapman J., and Hunter V.J. The use of antioxidant therapies during chemotherapy. Gynecol Oncol 88 3 (2003) 434-439
77. Kennedy D.D., Tucker K.L., Ladas E.D., Rheingold S.R., Blumberg J., and Kelly K.M. Low antioxidant vitamin intakes are associated with increases in adverse effects of chemotherapy in children with acute lymphoblastic leukemia. Am J Clin Nutr 79 6 (2004) 1029-1036
78. Weijl N.I., Elsendoorn T.J., Lentjes E.G., et al. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer 40 11 (2004) 1713-1723
79. Conklin K.A. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther 4 2 (2005) 110-130
80. Strasser F., Luftner D., Possinger K., et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24 21 (2006) 3394-3400
81. Kidd P.M. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev 5 1 (2000) 4-27
82. Wasser S.P. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol 60 3 (2002) 258-274
83. Borchers A.T., Stern J.S., Hackman R.M., Keen C.L., and Gershwin M.E. Mushrooms, tumors, and immunity. Proc Soc Exp Biol Med 221 4 (1999) 281-293
84. Akramiene D., Kondrotas A., Didziapetriene J., and Kevelaitis E. Effects of beta-glucans on the immune system. Medicina (Kaunas) 43 8 (2007) 597-606
85. Ohwada S., Ogawa T., Makita F., et al. Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters. Oncol Rep 15 4 (2006) 861-868
86. Ohwada S., Ikeya T., Yokomori T., et al. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer 90 5 (2004) 1003-1010
87. Sakamoto J., Morita S., Oba K., et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother 55 4 (2006) 404-411
88. Oba K., Teramukai S., Kobayashi M., Matsui T., Kodera Y., and Sakamoto J. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother 56 6 (2007) 905-911
89. Nakazato H., Koike A., Saji S., Ogawa N., and Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 343 8906 (1994) 1122-1126
90. Bao Y.X., Wong C.K., Leung S.F., et al. Clinical studies of immunomodulatory activities of Yunzhi-Danshen in patients with nasopharyngeal carcinoma. J Altern Complement Med 12 8 (2006) 771-776
91. Wong C.K., Bao Y.X., Wong E.L., Leung P.C., Fung K.P., and Lam C.W. Immunomodulatory activities of Yunzhi and Danshen in post-treatment breast cancer patients. Am J Chin Med 33 3 (2005) 381-395
92. Ghoneum M., Wimbley M., Salem F., McKlain A., ATtallah N., and Gill G. Immunomodulatory and Anticancer effects of Active Hemicellulose Compound (AHCC). International Journal of Immunotherapy 11 1 (1995) 23-28
93. Cowawintaweewat S., Manoromana S., Sriplung H., et al. Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment. Asian Pac J Allergy Immunol 24 1 (2006) 33-45
94. Matsui Y., Uhara J., Satoi S., et al. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol 37 1 (2002) 78-86
95. Yang D., Li S., Wang H., et al. [Prevention of postoperative recurrence of bladder cancer: a clinical study]. Zhonghua Wai Ke Za Zhi 37 8 (1999) 464-465 [in Chinese]
96. Kodama N., Komuta K., and Nanba H. Effect of Maitake (Grifola frondosa) D-Fraction on the activation of NK cells in cancer patients. J Med Food 6 4 (2003) 371-377
97. Chen X., Hu Z.P., Yang X.X., et al. Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer. Int Immunopharmacol 6 3 (2006) 499-508
98. Gao Y., Zhou S., Jiang W., Huang M., and Dai X. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest 32 3 (2003) 201-215
99. Gao Y., Tang W., Dai X., et al. Effects of water-soluble Ganoderma lucidum polysaccharides on the immune functions of patients with advanced lung cancer. J Med Food 8 2 (2005) 159-168
100. Ahn W.S., Kim D.J., Chae G.T., et al. Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy. Int J Gynecol Cancer 14 4 (2004) 589-594
101. Boros L.G., Nichelatti M., and Shoenfeld Y. Fermented wheat germ extract (Avemar) in the treatment of cancer and autoimmune diseases. Ann N Y Acad Sci 1051 (2005) 529-542
102. Garami M., Schuler D., Babosa M., et al. Fermented wheat germ extract reduces chemotherapy-induced febrile neutropenia in pediatric cancer patients. J Pediatr Hematol Oncol 26 10 (2004) 631-635
103. Jakab F., Shoenfeld Y., Balogh A., et al. A medical nutriment has supportive value in the treatment of colorectal cancer. Br J Cancer 89 3 (2003) 465-469
104. Demidov L., Manzjuk L., Kharkevitch G., Artamonova E., and Pirogova N. Antimetastatic effect of Avemar in high-risk melanoma patietns. 18th UICC International Cancer Congress (2002), Norway, Oslo
105. Mego M., Koncekova R., Mikuskova E., et al. Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Phase II study. Support Care Cancer 14 3 (2006) 285-290
106. Sugawara G., Nagino M., Nishio H., et al. Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized controlled trial. Ann Surg 244 5 (2006) 706-714
107. Besselink M.G., van Santvoort H.C., Buskens E., et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371 9613 (2008) 651-659
108. Alterio D., Jereczek-Fossa B.A., Fiore M.R., Piperno G., Ansarin M., and Orecchia R. Cancer treatment-induced oral mucositis. Anticancer Res 27 2 (2007) 1105-1125
109. Kaul R., Mishra B.K., Sutradar P., Choudhary V., and Gujral M.S. The role of Wobe-Mugos in reducing acute sequele of radiation in head and neck cancers-a clinical phase-III randomized trial. Indian J Cancer 36 2-4 (1999) 141-148
110. Nikoletti S., Hyde S., Shaw T., Myers H., and Kristjanson L.J. Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil. J Clin Nurs 14 6 (2005) 750-753
111. Biswal B.M., Zakaria A., and Ahmad N.M. Topical application of honey in the management of radiation mucositis: a preliminary study. Support Care Cancer 11 4 (2003) 242-248
112. Cerchietti L.C., Navigante A.H., Lutteral M.A., et al. Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 65 5 (2006) 1330-1337
113. Rubio I.T., Cao Y., Hutchins L.F., Westbrook K.C., and Klimberg V.S. Effect of glutamine on methotrexate efficacy and toxicity. Ann Surg 227 5 (1998) 772-778 discussion 778-80
114. Anderson P.M., Schroeder G., and Skubitz K.M. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer 83 7 (1998) 1433-1439
115. Skubitz K.M., and Anderson P.M. Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. J Lab Clin Med 127 2 (1996) 223-228
116. Anderson P.M., Ramsay N.K., Shu X.O., et al. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant 22 4 (1998) 339-344
117. Aquino V.M., Harvey A.R., Garvin J.H., et al. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant 36 7 (2005) 611-616
118. Cockerham M.B., Weinberger B.B., and Lerchie S.B. Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation. Ann Pharmacother 34 3 (2000) 300-303
119. Huang E.Y., Leung S.W., Wang C.J., et al. Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. Int J Radiat Oncol Biol Phys 46 3 (2000) 535-539
120. Okuno S.H., Woodhouse C.O., Loprinzi C.L., et al. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. Am J Clin Oncol 22 3 (1999) 258-261
121. Jebb S.A., Osborne R.J., Maughan T.S., et al. 5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. Br J Cancer 70 4 (1994) 732-735
122. El-Housseiny A.A., Saleh S.M., El-Masry A.A., and Allam A.A. The effectiveness of vitamin "E" in the treatment of oral mucositis in children receiving chemotherapy. J Clin Pediatr Dent 31 3 (2007) 167-170
123. Sung L., Tomlinson G.A., Greenberg M.L., et al. Serial controlled N-of-1 trials of topical vitamin E as prophylaxis for chemotherapy-induced oral mucositis in paediatric patients. Eur J Cancer 43 8 (2007) 1269-1275
124. Wadleigh R.G., Redman R.S., Graham M.L., Krasnow S.H., Anderson A., and Cohen M.H. Vitamin E in the treatment of chemotherapy-induced mucositis. Am J Med 92 5 (1992) 481-484
125. Ferreira P.R., Fleck J.F., Diehl A., et al. Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head Neck 26 4 (2004) 313-321
126. Lin L.C., Que J., Lin L.K., and Lin F.C. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. Int J Radiat Oncol Biol Phys 65 3 (2006) 745-750
127. Ertekin M.V., Koc M., Karslioglu I., and Sezen O. Zinc sulfate in the prevention of radiation-induced oropharyngeal mucositis: a prospective, placebo-controlled, randomized study. Int J Radiat Oncol Biol Phys 58 1 (2004) 167-174
128. Su C.K., Mehta V., Ravikumar L., et al. Phase II double-blind randomized study comparing oral aloe vera versus placebo to prevent radiation-related mucositis in patients with head-and-neck neoplasms. Int J Radiat Oncol Biol Phys 60 1 (2004) 171-177
129. Carl W., and Emrich L.S. Management of oral mucositis during local radiation and systemic chemotherapy: a study of 98 patients. J Prosthet Dent 66 3 (1991) 361-369
130. Mazokopakis E.E., Vrentzos G.E., Papadakis J.A., Babalis D.E., and Ganotakis E.S. Wild chamomile (Matricaria recutita L.) mouthwashes in methotrexate-induced oral mucositis. Phytomedicine 12 1-2 (2005) 25-27
131. Fidler P., Loprinzi C.L., O'Fallon J.R., et al. Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. Cancer 77 3 (1996) 522-525
132. Oberbaum M., Yaniv I., Ben-Gal Y., et al. A randomized, controlled clinical trial of the homeopathic medication TRAUMEEL S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. Cancer 92 3 (2001) 684-690
133. Gujral M.S., Patnaik P.M., Kaul R., et al. Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers. Cancer Chemother Pharmacol 47 Suppl (2001) S23-S28
134. Melichar B., Kohout P., Bratova M., Solichova D., Kralickova P., and Zadak Z. Intestinal permeability in patients with chemotherapy-induced stomatitis. J Cancer Res Clin Oncol 127 5 (2001) 314-318
135. Choi K., Lee S.S., Oh S.J., et al. The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. Clin Nutr 26 1 (2007) 57-62
136. Osterlund P., Ruotsalainen T., Peuhkuri K., et al. Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol 2 8 (2004) 696-703
137. Savarese D.M., Savy G., Vahdat L., Wischmeyer P.E., and Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 29 6 (2003) 501-513
138. Daniele B., Perrone F., Gallo C., et al. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Gut 48 1 (2001) 28-33
139. Savarese D., Al-Zoubi A., and Boucher J. Glutamine for irinotecan diarrhea. J Clin Oncol 18 2 (2000) 450-451
140. Li Y., Yu Z., Liu F., Tan L., Wu B., and Li J. Oral glutamine ameliorates chemotherapy-induced changes of intestinal permeability and does not interfere with the antitumor effect of chemotherapy in patients with breast cancer: a prospective randomized trial. Tumori 92 5 (2006) 396-401
141. Bozzetti F., Biganzoli L., Gavazzi C., et al. Glutamine supplementation in cancer patients receiving chemotherapy: a double-blind randomized study. Nutrition 13 7-8 (1997) 748-751
142. Kozelsky T.F., Meyers G.E., Sloan J.A., et al. Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. J Clin Oncol 21 9 (2003) 1669-1674
143. Osterlund P., Ruotsalainen T., Korpela R., et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer 97 8 (2007) 1028-1034
144. Urbancsek H., Kazar T., Mezes I., and Neumann K. Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus in patients with radiation-induced diarrhoea. Eur J Gastroenterol Hepatol 13 4 (2001) 391-396
145. Delia P., Sansotta G., Donato V., et al. Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. Am J Gastroenterol 97 8 (2002) 2150-2152
146. Delia P., Sansotta G., Donato V., et al. Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol 13 6 (2007) 912-915
147. Stillman M., and Cata J.P. Management of chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep 10 4 (2006) 279-287
148. Vahdat L., Papadopoulos K., Lange D., et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 7 5 (2001) 1192-1197
149. Stubblefield M.D., Vahdat L.T., Balmaceda C.M., Troxel A.B., Hesdorffer C.S., and Gooch C.L. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study. Clin Oncol (R Coll Radiol) 17 4 (2005) 271-276
150. Wang W.S., Lin J.K., Lin T.C., et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 12 3 (2007) 312-319
151. Pace A., Savarese A., Picardo M., et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 21 5 (2003) 927-931
152. Argyriou A.A., Chroni E., Koutras A., et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 64 1 (2005) 26-31
153. Argyriou A.A., Chroni E., Koutras A., et al. Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. J Pain Symptom Manage 32 3 (2006) 237-244
154. Argyriou A.A., Chroni E., Koutras A., et al. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer 14 11 (2006) 1134-1140
155. Nanthakomon T., and Pongrojpaw D. The efficacy of ginger in prevention of postoperative nausea and vomiting after major gynecologic surgery. J Med Assoc Thai 89 Suppl 4 (2006) S130-S136
156. Meyer K., Schwartz J., Crater D., and Keyes B. Zingiber officinale (ginger) used to prevent 8-Mop associated nausea. Dermatol Nurs 7 4 (1995) 242-244
157. Manusirivithaya S., Sripramote M., Tangjitgamol S., et al. Antiemetic effect of ginger in gynecologic oncology patients receiving cisplatin. Int J Gynecol Cancer 14 6 (2004) 1063-1069
158. Richardson J., Smith J.E., McIntyre M., Thomas R., and Pilkington K. Aloe vera for preventing radiation-induced skin reactions: a systematic literature review. Clin Oncol (R Coll Radiol) 17 6 (2005) 478-484
159. Olsen D.L., Raub Jr. W., Bradley C., et al. The effect of aloe vera gel/mild soap versus mild soap alone in preventing skin reactions in patients undergoing radiation therapy. Oncol Nurs Forum 28 3 (2001) 543-547
160. Williams M.S., Burk M., Loprinzi C.L., et al. Phase III double-blind evaluation of an aloe vera gel as a prophylactic agent for radiation-induced skin toxicity. Int J Radiat Oncol Biol Phys 36 2 (1996) 345-349
161. Maiche A.G., Grohn P., and Maki-Hokkonen H. Effect of chamomile cream and almond ointment on acute radiation skin reaction. Acta Oncol 30 3 (1991) 395-396
162. Pommier P., Gomez F., Sunyach M.P., D'Hombres A., Carrie C., and Montbarbon X. Phase III randomized trial of Calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer. J Clin Oncol 22 8 (2004) 1447-1453
163. Dewey A., Baughan C., Dean T., Higgins B., and Johnson I. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev 1 (2007) CD004597
164. Colomer R., Moreno-Nogueira J.M., Garcia-Luna P.P., et al. N-3 fatty acids, cancer and cachexia: a systematic review of the literature. Br J Nutr 97 5 (2007) 823-831
165. Elia M., Van Bokhorst-de van der Schueren M.A., Garvey J., et al. Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review. Int J Oncol 28 1 (2006) 5-23
166. Burns C.P., Halabi S., Clamon G.H., et al. Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. Clin Cancer Res 5 12 (1999) 3942-3947
167. Cerchietti L.C., Navigante A.H., and Castro M.A. Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer 59 1 (2007) 14-20
168. Burns C.P., Halabi S., Clamon G., et al. Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. Cancer 101 2 (2004) 370-378
169. Jatoi A., Rowland K., Loprinzi C.L., et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 22 12 (2004) 2469-2476
170. Mantovani G., Maccio A., Madeddu C., et al. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev 15 5 (2006) 1030-1034
171. Gothard L., Cornes P., Earl J., et al. Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer. Radiother Oncol 73 2 (2004) 133-139
172. Kasseroller R.G., and Schrauzer G.N. Treatment of secondary lymphedema of the arm with physical decongestive therapy and sodium selenite: a review. Am J Ther 7 4 (2000) 273-279
173. Micke O., Bruns F., Mucke R., et al. Selenium in the treatment of radiation-associated secondary lymphedema. Int J Radiat Oncol Biol Phys 56 1 (2003) 40-49
174. Cluzan R.V., Pecking A.P., Mathiex-Fortunet H., and Leger Picherit E. Efficacy of BN165 (Ginkor Fort) in breast cancer related upper limb lymphedema: a preliminary study. Lymphology 37 2 (2004) 47-52
175. Pecking A.P. Evaluation by lymphoscintigraphy of the effect of a micronized flavonoid fraction (Daflon 500 mg) in the treatment of upper limb lymphedema. Int Angiol 14 3 Suppl 1 (1995) 39-43
176. Pecking A.P., Fevrier B., Wargon C., and Pillion G. Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer). Angiology 48 1 (1997) 93-98
177. Olszewski W. Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema. Angiology 51 1 (2000) 25-29
178. Cluzan R.V., Alliot F., Ghabboun S., and Pascot M. Treatment of secondary lymphedema of the upper limb with CYCLO 3 FORT. Lymphology 29 1 (1996) 29-35
179. Brooker S., Martin S., Pearson A., et al. Double-blind, placebo-controlled, randomised phase II trial of IH636 grape seed proanthocyanidin extract (GSPE) in patients with radiation-induced breast induration. Radiother Oncol 79 1 (2006) 45-51
180. Bruns F., Micke O., and Bremer M. Current status of selenium and other treatments for secondary lymphedema. J Support Oncol 1 2 (2003) 121-130
181. Bruns F., Buntzel J., Mucke R., Schonekaes K., Kisters K., and Micke O. Selenium in the treatment of head and neck lymphedema. Med Princ Pract 13 4 (2004) 185-190
182. Zimmermann T., Leonhardt H., Kersting S., Albrecht S., Range U., and Eckelt U. Reduction of postoperative lymphedema after oral tumor surgery with sodium selenite. Biol Trace Elem Res 106 3 (2005) 193-203
183. de Souza Fede A.B., Bensi C.G., Trufelli D.C., et al. Multivitamins do not improve radiation therapy-related fatigue: results of a double-blind randomized crossover trial. Am J Clin Oncol 30 4 (2007) 432-436
184. Cruciani R.A., Dvorkin E., Homel P., et al. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Ann N Y Acad Sci 1033 (2004) 168-176
185. Graziano F., Bisonni R., Catalano V., et al. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. Br J Cancer 86 12 (2002) 1854-1857
186. Gramignano G., Lusso M.R., Madeddu C., et al. Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition 22 2 (2006) 136-145
187. Cruciani R.A., Dvorkin E., Homel P., et al. Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. J Pain Symptom Manage 32 6 (2006) 551-559
188. Jacobson J.S., Troxel A.B., Evans J., et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 19 10 (2001) 2739-2745
189. Pockaj B.A., Loprinzi C.L., Sloan J.A., et al. Pilot evaluation of black cohosh for the treatment of hot flashes in women. Cancer Invest 22 4 (2004) 515-521
190. Pockaj B.A., Gallagher J.G., Loprinzi C.L., et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol 24 18 (2006) 2836-2841
191. Hernandez Munoz G., and Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas 44 Suppl 1 (2003) S59-S65
192. Rebbeck T.R., Troxel A.B., Norman S., et al. A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. Int J Cancer 120 7 (2007) 1523-1528
193. Zepelin H.H., Meden H., Kostev K., Schroder-Bernhardi D., Stammwitz U., and Becher H. Isopropanolic black cohosh extract and recurrence-free survival after breast cancer. Int J Clin Pharmacol Ther 45 3 (2007) 143-154
194. Li N., Sun Z., Han C., and Chen J. The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proc Soc Exp Biol Med 220 4 (1999) 218-224
195. Halder A., Raychowdhury R., Ghosh A., and De M. Black tea (Camellia sinensis) as a chemopreventive agent in oral precancerous lesions. J Environ Pathol Toxicol Oncol 24 2 (2005) 141-144
196. Bettuzzi S., Brausi M., Rizzi F., Castagnetti G., Peracchia G., and Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 66 2 (2006) 1234-1240
197. Pantuck A.J., Leppert J.T., Zomorodian N., et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 12 13 (2006) 4018-4026
198. Schroder F.H., Roobol M.J., Boeve E.R., et al. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol 48 6 (2005) 922-930 discussion 930-921
199. Ansari M.S., and Gupta N.P. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer. Urol Oncol 22 5 (2004) 415-420
200. Ansari M.S., and Gupta N.P. A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. BJU Int 92 4 (2003) 375-378 discussion 378
201. Jatoi A., Burch P., Hillman D., et al. A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group. Urology 69 2 (2007) 289-294